Related Experiment Videos
Octreotide: a long-acting somatostatin analog
1Vanderbilt University Medical Center Pharmacy, Nashville, Tennessee.
The American Journal of the Medical Sciences
|October 1, 1990
Summary
Octreotide, a somatostatin analog, shows promise for treating neuroendocrine disorders like carcinoid syndrome and VIP-secreting tumors. Further long-term studies are needed to fully assess its efficacy and safety for various conditions.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Octreotide is a somatostatin analog introduced into clinical practice.
- Its use targets diseases with abnormal somatostatin secretion.
- Early data derived from uncontrolled compassionate use.
Purpose of the Study:
- To critically review available clinical information on octreotide.
- To evaluate its therapeutic potential in various neuroendocrine disorders.
- To identify areas requiring further research, particularly long-term studies.
Main Methods:
- Critical review of existing clinical information on octreotide.
- Analysis of data from compassionate use and early clinical experiences.
- Assessment of therapeutic effects on specific disease manifestations.
Main Results:
- Octreotide shows promise in acute treatment of carcinoid syndrome and crisis.
- It ameliorates symptoms in VIP-secreting tumors and other gut neuroendocrine tumors.
- Potential exists for growth-hormone-secreting tumors, but long-term data is lacking.
Conclusions:
- Octreotide is a promising therapeutic tool for specific neuroendocrine disorders.
- More long-term studies are necessary to evaluate disease progression and adverse effects.
- Current indications may evolve with increased understanding of the drug's applications and limitations.